View Older Stories View More Recent Stories

Dec 9, 2024 08:05AM Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer
Nov 25, 2024 05:09PM Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
Nov 13, 2024 05:05PM Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 6, 2024 04:05PM Guardant Health Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Nov 1, 2024 07:00AM Guardant Health to Participate in Upcoming Investor Conferences
Oct 30, 2024 09:30AM Guardant Health Named to TIME’s List of the Best Inventions of 2024
Oct 28, 2024 08:05AM Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Colorectal Cancer Screening at ACG 2024
Oct 24, 2024 05:06PM Guardant Health (GH) Appoints Roberto A. Mignone to its Board
Oct 24, 2024 05:05PM Roberto A. Mignone Joins Guardant Health Board of Directors
Oct 15, 2024 04:05PM Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024
Sep 18, 2024 08:05AM GOZILA Study Published in Nature Medicine Shows Patients With Advanced Cancer Who Receive Liquid Biopsy-Guided Treatment Using Guardant360 CDx Survive Twice as Long
Sep 13, 2024 02:00AM Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
Sep 10, 2024 08:00AM Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy
Aug 27, 2024 04:05PM Guardant Health to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 22, 2024 05:00PM Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
Aug 8, 2024 04:05PM Guardant Health to Participate in Upcoming Investor Conferences
Aug 7, 2024 04:05PM Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
Aug 7, 2024 08:05AM Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
Aug 1, 2024 08:33AM Guardant Health's (GH) FDA-approved Shield Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
Aug 1, 2024 08:30AM Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
Aug 1, 2024 08:00AM Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
Jul 29, 2024 07:34AM Guardant Health's (GH) Shield Blood Test Approved by FDA as Primary Screening Option, Clearing Path for Medicare Reimbursement
Jul 29, 2024 06:30AM Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
Jul 24, 2024 04:05PM Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
Jul 23, 2024 08:17AM Guardant Health (GH) Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360 Test
Jul 23, 2024 08:05AM Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
Jul 18, 2024 05:01PM Guardant Health (GH) Appoints Manuel Hidalgo Medina to its Board
Jul 18, 2024 05:00PM Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
Jun 4, 2024 08:05AM Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
Jun 3, 2024 09:18AM Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical t
May 31, 2024 08:05AM Guardant Health Named to TIME100 Most Influential Companies
May 30, 2024 08:05AM Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
May 24, 2024 08:20AM Guardant Health (GH): FDA Advisory Committee Panel Strongly Recommends Approval of Shield Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
May 23, 2024 07:03PM FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
May 23, 2024 07:05AM Guardant Health (GH) Reports FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
May 23, 2024 07:05AM Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
May 22, 2024 04:05PM Guardant Health to Participate in Upcoming Investor Conferences
May 21, 2024 08:06AM Guardant Health (GH) Receives EU IVDR Certification for Guardant360 CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
May 21, 2024 08:05AM Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
May 17, 2024 08:05AM Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2024 08:05AM Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
May 9, 2024 04:05PM Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
May 7, 2024 04:05PM Guardant Health to Participate in Upcoming Investor Conferences
May 7, 2024 08:00AM Guardant Health Surpasses 500 Peer-Reviewed Publications Milestone
Apr 22, 2024 08:54AM Guardant Health (GH) Announces FDA Advisory Panel Review of Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Apr 22, 2024 08:52AM FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Apr 18, 2024 04:05PM Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
Apr 3, 2024 08:05AM Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
Mar 13, 2024 05:00PM Guardant Health (GH) Announces Publication of ECLIPSE Study Data
Mar 13, 2024 05:00PM Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
View More Recent Stories View Older Stories